- Home
- ROIV vs CELH Comparison
ROIV vs CELH Comparison
Compare ROIV & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | CELH |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 10.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | CELH |
|---|---|---|
| Price | $21.94 | $43.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 17 |
| Target Price | $21.94 | ★ $64.18 |
| AVG Volume (30 Days) | ★ 6.7M | 6.2M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | $20,329,000.00 | ★ $2,125,838,000.00 |
| Revenue This Year | N/A | $83.38 |
| Revenue Next Year | $376.94 | $32.58 |
| P/E Ratio | ★ N/A | $362.79 |
| Revenue Growth | N/A | ★ 55.07 |
| 52 Week Low | $8.73 | $21.10 |
| 52 Week High | $22.45 | $66.74 |
Technical Indicators
Market Signals| Indicator | ROIV | CELH |
|---|---|---|
| Relative Strength Index (RSI) | 68.21 | 46.28 |
| Support Level | $20.14 | $40.65 |
| Resistance Level | $21.48 | $45.23 |
| Average True Range (ATR) | 0.66 | 1.80 |
| MACD | -0.02 | 0.99 |
| Stochastic Oscillator | 87.12 | 80.85 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.